06MA Stock Chart & Stats
€5.45
€0.00(0.00%)
At close: 4:00 PM EDT
€5.45
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.10 - €7.60
Previous CloseN/A
Volume0.00
Average Volume (3M)19.00
Market Cap
€455.04M
Enterprise Value€348.44M
Total Cash (Recent Filing)€133.68M
Total Debt (Recent Filing)€59.50M
Price to Earnings (P/E)33.5
Beta0.96
Next Earnings
Oct 28, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding59,067,184
10 Day Avg. Volume0
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)1.09
Price to Sales (P/S)1.09
P/FCF Ratio30.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.16
Revenue Forecast (FY)€245.81M
Bulls Say, Bears Say
Bulls Say
Medical Segment GrowthMedical is becoming a larger and more profitable growth engine, with strong revenue expansion and a 31% EBITDA margin in Q2. Its patient-specific solutions, device relationships, and expanding clinical applications can support durable adoption and improve the company’s overall earnings mix.
Net Cash And Cash GenerationThe net cash position and improving operating cash flow provide financial flexibility to fund R&D, product development, and strategic initiatives without relying heavily on external capital. This strengthens resilience while giving management capacity to pursue growth and absorb business-cycle variability.
Strategic Product And Portfolio FocusThe company is concentrating resources on software, medical, aerospace, and other higher-value applications while extending its workflow platform through new products and an HP collaboration. Divestments may simplify execution and improve the long-term quality of the business mix.
Bears Say
Software Revenue And Transition PressureSoftware revenue weakness and extended customer decisions can slow the segment’s growth, while the transition from perpetual licenses to subscriptions may temporarily pressure reported revenue and profitability. Continued investment is required before recurring revenue benefits fully offset the transition costs.
Manufacturing Near BreakevenManufacturing has not yet demonstrated consistently attractive profitability, as the segment remains near breakeven and prototyping demand is weak. This limits consolidated margin expansion and leaves earnings more dependent on stronger Medical performance and successful higher-value applications.
Uneven Cash ConversionAlthough recent cash generation improved, inconsistent free cash flow conversion indicates that working capital and investment requirements can materially separate reported earnings from available cash. This may constrain the pace of reinvestment or shareholder returns if volatility persists across operating cycles.
Materialise News
06MA FAQ
What was Materialise NV’s price range in the past 12 months?
Materialise NV lowest stock price was €4.10 and its highest was €7.60 in the past 12 months.
What is Materialise NV’s market cap?
Materialise NV’s market cap is €455.04M.
When is Materialise NV’s upcoming earnings report date?
Materialise NV’s upcoming earnings report date is Oct 28, 2026 which is in 3 days.
How were Materialise NV’s earnings last quarter?
Materialise NV released its earnings results on Aug 27, 2026. The company reported €0.06 earnings per share for the quarter, beating the consensus estimate of €0.04 by €0.02.
Is Materialise NV overvalued?
According to Wall Street analysts Materialise NV’s price is currently Overvalued.
Does Materialise NV pay dividends?
Materialise NV does not currently pay dividends.
What is Materialise NV’s EPS estimate?
Materialise NV’s EPS estimate is 0.02.
How many shares outstanding does Materialise NV have?
Materialise NV has 59,067,184 shares outstanding.
What happened to Materialise NV’s price movement after its last earnings report?
Materialise NV reported an EPS of €0.06 in its last earnings report, beating expectations of €0.04. Following the earnings report the stock price went up 14.679%.
Which hedge fund is a major shareholder of Materialise NV?
Currently, no hedge funds are holding shares in DE:06MA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Materialise Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:06MA Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.94%
12-Months-Change
Fundamentals
Return on Equity
5.40%
Trailing 12-Months
Asset Growth
0.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Materialise NV
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
06MA Company Deck
06MA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive picture: healthy consolidated revenue growth (+8% Q2), clear margin and profitability improvements (adjusted EBITDA +16%, adjusted EBIT expansion), strong cash generation and net cash position, and strategic product and portfolio actions (CO-AM launches, Replasia investment, divestments) that position the company for scalable growth. Offsetting risks include a modest decline in Software revenue and near-term seasonality/costs (asset impairment, working capital increase), and ongoing weakness in certain Manufacturing subsegments (prototyping demand). On balance, the operational and financial momentum and the upgrade to adjusted EBIT guidance outweigh the contained headwinds reported.View all DE:06MA earnings summaries